(Hypertension. 1999;34:586-589.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
From the Department of Internal Medicine (C.S., P.N., U.S.) and the Botnar Center for Clinical Research, Centre Hospitalier Universitaire Vaudois, and Institute of Physiology (L.T.), University of Lausanne, Switzerland.
Correspondence to Dr Urs Scherrer, Department of Internal Medicine, BH 10.642, CHUV, CH-1011 Lausanne, Switzerland. E-mail Urs.Scherrer{at}chuv.hospvd.ch
| Abstract |
|---|
|
|
|---|
Key Words: nervous system, sympathetic insulin vasodilation hyperinsulinism glucose clamp technique glucose nitric oxide
| Introduction |
|---|
|
|
|---|
To examine the role played by neural versus local vasodilator mechanisms and their interplay with neural vasoconstrictor mechanisms, we compared, in lean subjects who had undergone regional sympathectomy for hyperhidrosis, the vasodilator responses to insulin infusion in the sympathetically denervated and innervated limb. To gain additional insight into underlying mechanisms, we studied effects of NO synthase inhibition on vascular responses to insulin infusion in the denervated limb.
| Methods |
|---|
|
|
|---|
General Procedures
Subjects were studied in the supine position. Heart rate (ECG),
respiratory excursions (Pneumobelt), blood pressure (Finapres blood
pressure monitor, Ohmeda),5 and limb blood flow
(venous occlusion plethysmography) were recorded continuously on an
electrostatic recorder. Intravenous catheters were
inserted in a right and left antecubital vein, one for substrate and
drug infusion and the other for blood sampling.
Measurement of Muscle Blood Flow
Blood flow in an ipsilateral forearm and calf was measured with
venous occlusion plethysmography, with the use of mercury-in-silastic
strain gauges.5 Both limbs were elevated 10 to 15 cm above
the level of the right atrium to collapse the veins. The circulation to
the hand and the foot was arrested by inflating a cuff around the wrist
and the ankle to suprasystolic pressure during blood flow
determinations.
Experimental Protocols
Protocol 1: Hyperinsulinemic Euglycemic
Clamp Alone
After instrumentation and 1 hour of baseline measurements,
the subjects received a primed continuous infusion of crystalline
insulin (Actrapid HM, Novo Industri S/A) at a rate of 6 pmol/kg per
minute (1 mU/kg per minute) for 2 hours. Euglycemia was maintained by
determining plasma glucose concentration every 5 minutes and
periodically adjusting a variable infusion of 20%
dextrose.6 Hypokalemia was prevented by administration of
KCl infused at a rate of 3 mmol/h. Hemodynamic
measurements were recorded for 5 minutes every 15 minutes
throughout the study. Blood samples were collected every 30 minutes for
analysis of substrate and hormone concentrations.
To demonstrate the efficacy of thoracic sympathectomy, we measured blood pressure and limb blood flow responses to 2 minutes of immersion of the hand in ice water (cold pressor test) and compared vasoconstrictor responses in the denervated and innervated limbs during the second minute of this test. Vasoconstrictor responses to immersion of the hand in ice water in the sympathetically denervated forearm were abolished; during the second minute of the cold pressor test, vascular resistance had increased by 48±20% in the innervated limb, whereas it had decreased by 17±5% in the denervated limb (P<0.02 innervated versus denervated limbs).
To document that differential blood flow responses to insulin/glucose infusion in the forearm and the calf were related specifically to sympathetic denervation (rather than to differential responses of forearm and calf blood flow to insulin infusion), we also studied 3 patients who had undergone both thoracic and lumbar sympathectomy (3 men; mean±SE age, 35±7 years; body mass index, 23.5±1.7 kg/m2) and 4 control subjects (4 men; mean±SE age, 24±1 years; body mass index, 22.7±0.6 kg/m2).
Protocol 2: Hyperinsulinemic Euglycemic
Clamp Performed During Concomitant Systemic L-NMMA Infusion
Six of the 9 subjects (2 men and 4 women; mean±SE age,
38±5 years; body mass index, 21.4±1.0 kg/m2)
returned for this protocol. The protocol was identical to protocol 1,
except that during the second 30 minutes of baseline and during the
entire 2-hour clamp, the subjects received (in randomized order) either
a concomitant systemic L-NMMA infusion (50 µg/kg per minute) or a
vehicle (normal saline) infusion. To demonstrate that the
L-NMMAinduced hemodynamic effects plateau at the time
the clamp was commenced, in 10 healthy subjects we infused L-NMMA at
the same rate over 60 minutes. We found that mean arterial
pressure increased significantly (P<0.01) from 77±2
mm Hg at baseline to 84±2 mm Hg after 30 minutes of infusion
and then remained unchanged at 86±2 and 85±2 mm Hg after 45 and
60 minutes of infusion, respectively (P>0.1, 30 versus 60
minutes). In 4 of these subjects, the L-NMMA infusion was continued for
a total of 150 minutes, and, in accordance with data by Dijkhorst-Oei
and Koomans,7 arterial pressure did not
increase any further (88±3 and 90±4 mm Hg at 60 and 150
minutes, respectively; P>0.1). Consistent with
previous findings,8 limb blood flow and vascular
resistance remained unchanged; values for forearm blood flow at
baseline and after 60 minutes of infusion were 2.76±0.18 and
2.77±0.19 mL/100 mL per minute, respectively, and those for vascular
resistance were 29.0±1.6 and 33.0±2.8 U, respectively. In the 4
subjects in whom the infusion was continued for a total of 150 minutes,
forearm blood flow (2.43±0.30 versus 2.52±0.20 mL/min per 100 mL) and
vascular resistance (36.3±4.9 versus 37.1 U) did not change between 60
and 150 minutes of infusion.
To examine whether the L-NMMAinduced hemodynamic effects were related specifically to NO synthase inhibition, at the end of the 2-hour clamp, insulin/glucose infusion was continued for another 30 minutes, whereas the L-NMMA infusion was replaced by L-arginine (50 mg/kg over 10 minutes). Hemodynamic measurements were repeated 15 minutes after the end of L-arginine infusion.
Analytical Methods
Plasma glucose was determined in duplicate by the glucose
oxidase method on a Beckman glucose analyzer (Beckman
Instruments). Plasma insulin was measured by
radioimmunoassay.2
Data Analysis
Mean arterial pressure was calculated as
diastolic pressure plus one third pulse pressure. Limb
vascular resistance was calculated as mean arterial
pressure in millimeters of mercury divided by blood flow in milliliters
per minute per 100 mL tissue, expressed in units.
The 5 minutes of data from forearm and calf blood flow, blood pressure, and heart rate collected every 15 minutes were averaged to a single value. Whole body glucose uptake was assumed to be equal to exogenous glucose infusion necessary to maintain euglycemia during the clamp2 and was averaged for 30-minute periods. Statistical analysis was performed by ANOVA for repeated measures followed by Fisher's post hoc test. For single comparisons, the 2-tailed paired t test or the Wilcoxon signed rank test was used, as appropriate. A P value <0.05 was considered statistically significant. Data are given as mean±SE.
| Results |
|---|
|
|
|---|
|
|
In the 3 subjects who had undergone both lumbar and thoracic sympathectomy, >80% of the insulin-induced vasodilation in the denervated calf occurred within the first 30 minutes, and the time course was virtually superimposable to the one observed in their denervated forearm (and to the one observed in the denervated forearm of the subjects who had undergone thoracic sympathectomy alone). In the 4 control subjects, as expected, the insulin-induced vasodilation in the innervated forearm and calf was slower in onset compared with the one observed in the patients with denervated limbs, and blood flow continued to increase progressively throughout the clamp. Blood flow values at time 0, 30, 60, 90, and 120 minutes of the hyperinsulinemic clamp in the innervated forearm were 2.0±0.2, 2.5±0.4, 3.0±0.3, 3.3±0.4, and 3.6±0.4 mL/min per 100 mL and in the innervated calf were 2.0±0.2, 2.6±0.6, 2.9±0.7, 3.1±0.7, and 3.3±1.0 mL/min per 100 mL, respectively.
Protocol 2
L-NMMA infusion did not have any detectable effect on plasma
glucose and insulin concentrations at baseline and during the
insulin/glucose infusion (Table 2).
|
L-NMMA infusion significantly (P<0.05) increased baseline mean arterial pressure and markedly altered the blood pressure and forearm blood flow responses to insulin/glucose infusion (Table 2). While mean arterial pressure remained unchanged during the clamp plus vehicle infusion, it increased significantly when the clamp was performed during concomitant L-NMMA infusion (Table 2). In the denervated forearm, L-NMMA infusion attenuated the insulin-induced vasodilation. At the end of the clamp, forearm blood flow had increased by 30±6% during vehicle infusion but by only 10±5% during L-NMMA infusion, whereas the forearm vascular resistance had decreased by 19±5% during vehicle infusion but remained unchanged (-1±4%) during L-NMMA infusion (Figure 2). When, at the end of clamp, L-NMMA infusion was replaced by L-arginine infusion, the altered hemodynamic responses to insulin were restored. Mean arterial pressure decreased from 104±5 to 95±5 mm Hg (P<0.01), and forearm blood flow increased from 2.37±0.23 to 2.73±0.33 mL/100 mL per minute (P=0.07).
|
In contrast to these marked hemodynamic actions, L-NMMA did not have any detectable effect on whole body glucose uptake. During the last 30 minutes of the clamp, whole body glucose uptake was 7.3±0.6 and 7.5±1.2 mg/kg per minute during vehicle and L-NMMA infusion, respectively (Figure 2).
| Discussion |
|---|
|
|
|---|
The experimental model of regional sympathectomy not only allowed us to study the potential contribution of sympathetic vasodilator (nitrergic) nerves to insulin vasodilation, but also permitted us to examine whether sympathetic vasoconstrictor tone modulates such vasodilation. In innervated limbs, as in the present study, insulin-induced vasodilation consistently has been found to be slow in onset and to occur progressively.1 In contrast, in the denervated forearm vasodilation rapidly reached its maximum (during the first 30 to 45 minutes of insulin infusion) and remained stable thereafter. This finding is specific for denervation and not related to differential vasodilator responses to insulin infusion in the forearm and the calf, as evidenced by the studies in the patients who had undergone both lumbar and thoracic sympathectomy and in the control subjects. Consistent with the rapid onset of the vasodilation in sympathetically denervated limbs in vivo, insulin rapidly stimulates NO release in cultured human vascular endothelial cells9 and in vascular ring preparations in vitro.10
Previous findings indicated that prevention of the insulin-induced sympathetic activation by dexamethasone abolishes the stimulation of muscle blood flow during insulin infusion in humans.11 Taken together with the present findings, these earlier findings suggest that the baseline sympathetic vasoconstrictor tone prevents the direct vasodilator action of insulin in innervated limbs, because it can only be demonstrated in the absence (surgical sympathectomy), but not in the presence (dexamethasone studies), of sympathetic innervation. Consistent with this hypothesis, in patients with autonomic failure (sympathetic denervation as an experiment of nature), insulin infusion evokes vasodilation and hypotension.1 Second, in innervated limbs, stimulation, by insulin, of sympathetic vasodilator outflow is necessary to induce vasodilation, because the suppression of the insulin-induced sympathetic activation also abolishes the vasodilation.
To examine whether NO contributes to the direct local vasodilator action of insulin, we examined the effects of systemic inhibition of NO synthase by L-NMMA infusion on insulin-induced stimulation of blood flow in sympathectomized limbs. We found that L-NMMA infusion markedly attenuated the insulin-induced stimulation of muscle blood flow and decrease in vascular resistance in sympathectomized limbs. This effect was related specifically to NO synthase inhibition, as evidenced by the L-arginine studies.
Insulin resistance is a common feature of essential hypertension,12 13 and preliminary evidence suggests that endothelial dysfunction may contribute to impaired muscle glucose uptake.14 In rats, arterial hypertension induced by L-NMMA infusion impairs insulin-stimulated glucose uptake.15 In contrast, the present findings suggest that in humans, a clinically relevant impairment in NO release (as evidenced by the increase in baseline arterial pressure) does not alter insulin stimulation of glucose uptake.
In summary, we have used an experimental model (regional sympathectomy) to study vascular actions of insulin in the presence and absence of sympathetic vasodilator and vasoconstrictor innervation in humans. We found that insulin has a direct vasodilator action in the skeletal muscle vasculature in vivo. This direct vasodilator action is mediated by stimulation of NO release and appears to be masked by the sympathetic vasoconstrictor tone in innervated limbs.
| Acknowledgments |
|---|
Received February 9, 1999; first decision February 25, 1999; accepted June 7, 1999.
| References |
|---|
|
|
|---|
2. Vollenweider P, Tappy L, Randin D, Schneiter P, Jéquier E, Nicod P, Scherrer U. Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest. 1993;92:147154.
3. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest. 1994;94:25112515.
4. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest. 1994;94:11721179.
5.
Randin D, Vollenweider P, Tappy L, Jéquier
E, Nicod P, Scherrer U. Effects of adrenergic and cholinergic blockade
on insulin-induced stimulation of calf blood flow in humans.
Am J Physiol. 1994;266:R809R816.
6. Vollenweider P, Randin D, Tappy L, Jéquier E, Nicod P, Scherrer U. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest. 1994;93:23652371.
7. Dijkhorst-Oei LT, Koomans HA. Effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. Nephrol Dial Transplant. 1998;587593.
8.
Owlya R, Vollenweider L, Trueb L, Sartori C,
Lepori M, Nicod P, Scherrer U. Cardiovascular and
sympathetic effects of nitric oxide inhibition at rest and during
static exercise in humans. Circulation. 1997;96:38973903.
9. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin: direct measurement in vascular endothelial cells. J Clin Invest. 1996;98:894898.[Medline] [Order article via Infotrieve]
10.
Chen Y-L, Messina EJ. Dilation of isolated skeletal
muscle arterioles by insulin is endothelium dependent
and nitric oxide mediated. Am J Physiol. 1996;270:H2120H2124.
11.
Scherrer U, Vollenweider P, Randin D, Jéquier E,
Nicod P, Tappy L. Suppression of insulin-induced sympathetic activation
and vasodilation by dexamethasone in humans.
Circulation. 1993;88:388394.
12. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350357.[Abstract]
13. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z. Hyperinsulinemia: a link between hypertension, obesity, and glucose intolerance. J Clin Invest. 1985;75:809817.
14.
Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell
JMC. Endothelial nitric oxide production and
insulin sensitivity: a physiological link with
implications for pathogenesis of cardiovascular
disease. Circulation. 1996;93:13311333.
15.
Baron AD, Zhu J-S, Marshall S, Irsula O, Brechtel G,
Keech C. Insulin resistance after hypertension induced by the nitric
oxide synthesis inhibitor L-NMMA in rats. Am J
Physiol. 1995;269:E709E715.
This article has been cited by other articles:
![]() |
M. A. Potenza, F. Addabbo, and M. Montagnani Vascular actions of insulin with implications for endothelial dysfunction Am J Physiol Endocrinol Metab, September 1, 2009; 297(3): E568 - E577. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. V. Menon, D. Arbique, Z. Wang, B. Adams-Huet, R. J. Auchus, and W. Vongpatanasin Differential Effects of Chlorthalidone Versus Spironolactone on Muscle Sympathetic Nerve Activity in Hypertensive Patients J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1361 - 1366. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon Cardiovascular Actions of Insulin Endocr. Rev., August 1, 2007; 28(5): 463 - 491. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-a Kim, M. Montagnani, K. K. Koh, and M. J. Quon Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms Circulation, April 18, 2006; 113(15): 1888 - 1904. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Levesque, M. Santure, M. Pitre, A. Nadeau, and H. Bachelard Cholinergic Involvement in Vascular and Glucoregulatory Actions of Insulin in Rats Diabetes, February 1, 2006; 55(2): 398 - 404. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sydow, C. E Mondon, and J. P Cooke Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA Vascular Medicine, July 1, 2005; 10(1_suppl): S35 - S43. [Abstract] [PDF] |
||||
![]() |
K. Sydow, C. E Mondon, and J. P Cooke Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA Vascular Medicine, May 1, 2005; 10(2_suppl): S35 - S43. [Abstract] [PDF] |
||||
![]() |
M. Kooijman, G. A. Rongen, P. Smits, and M. T.E. Hopman Preserved {alpha}-Adrenergic Tone in the Leg Vascular Bed of Spinal Cord-Injured Individuals Circulation, November 11, 2003; 108(19): 2361 - 2367. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Vincent, E. J. Barrett, J. R. Lindner, M. G. Clark, and S. Rattigan Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E123 - E129. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Eringa, C. D.A. Stehouwer, T. Merlijn, N. Westerhof, and P. Sipkema Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles Cardiovasc Res, December 1, 2002; 56(3): 464 - 471. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. F. Jordan, V. Gregoire, R. J. Demeure, P. Sonveaux, O. Feron, J. O'Hara, V. P. Vanhulle, N. Delzenne, and B. Gallez Insulin Increases the Sensitivity of Tumors to Irradiation: Involvement of an Increase in Tumor Oxygenation Mediated by a Nitric Oxide-dependent Decrease of the Tumor Cells Oxygen Consumption Cancer Res., June 1, 2002; 62(12): 3555 - 3561. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Charkoudian, J. H. Eisenach, J. L. D. Atkinson, R. D. Fealey, and M. J. Joyner Effects of chronic sympathectomy on locally mediated cutaneous vasodilation in humans J Appl Physiol, February 1, 2002; 92(2): 685 - 690. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rask-Madsen, N. Ihlemann, T. Krarup, E. Christiansen, L. Kober, C. Nervil Kistorp, and C. Torp-Pedersen Insulin Therapy Improves Insulin-Stimulated Endothelial Function in Patients With Type 2 Diabetes and Ischemic Heart Disease Diabetes, November 1, 2001; 50(11): 2611 - 2618. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Westerbacka, A. Uosukainen, S. Makimattila, A. Schlenzka, and H. Yki-Jarvinen Insulin-Induced Decrease in Large Artery Stiffness Is Impaired in Uncomplicated Type 1 Diabetes Mellitus Hypertension, May 1, 2000; 35(5): 1043 - 1048. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |